Cost-Effectiveness Analysis of Atezolizumab and Bevacizumab versus Sorafenib in the Treatment of Hepatocellular Carcinoma: A Systematic Review

Bander Balkhi, Abdulaziz Alotaibi and Faris Alotaibi Author informationArticle notesCopyright and License information Pharmacoeconomics Research Unit, Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, SAUDI ARABIA Corresponding author. Correspondence Dr. Bander Balkhi Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh-11451, SAUDI ARABIA. Received: 02 October 2022; Revised: 10 November